Humana Inc.

This review draws on Humana's 2025 annual figures, the first-quarter 2026 10-Q MD&A, and the 10-K risk-factor excerpt. In the supplied text, the risk-factor section is mostly a table of contents and forward-looking statement language, so specific risk wording is limited here. The business is large and concentrated. In 2025, individual Medicare Advantage premiums were $90.403 billion, or 70.3% of consolidated premiums and services revenue, and state-based contracts added $14.477 billion. Revenue has grown from $56.91 billion in 2018 to $129.66 billion in 2025, yet operating income moved within a narrower band, from $3.1 billion to $2.7 billion over the same span, with a peak of $4.99 billion in 2020. That gap is the central thing a reader can check: top-line growth has not translated into a steadily rising operating profit. The first-quarter 2026 MD&A shows a similar pattern. Net income attributable to Humana fell about 4%, and diluted EPS fell from $10.30 to $9.83. Management attributes part of the comparison to put/call valuation adjustments, which were negative $34 million in 2026 versus a $163 million gain in 2025, and to value creation charges. Because these items move results in both directions, readers may want to look at the MD&A adjustment table rather than only the headline earnings figure. No Beneish M-Score, Piotroski F-Score, Altman Z-Score, or Fog Index was supplied for this filing, so none is assessed here, and no forensic conclusion should be drawn from their absence. Readers may want to look at the cash flow statement and the Note 18 segment disclosures for a fuller view.

Catalyst.The MD&A points to the MaxHealth acquisition, a Florida primary care platform closed February 13, 2026 for approximately $908 million in cash net of cash acquired, and to the CenterWell segment's pharmacy, primary care and home solutions as growth levers. Management says its integrated care delivery model is positioning the company for long-term growth in membership and earnings. At March 31, 2026, approximately 4,088,800 individual Medicare Advantage members, or 64%, were in value-based relationships, up from 3,501,700 members a year earlier. Revenues were $129.66 billion for 2025, up from $117.76 billion in 2024, roughly 10% growth. Net income attributable to Humana for the first quarter of 2026 was $1.19 billion, or $9.83 per diluted share, compared with $1.24 billion, or $10.30, a year earlier.

Hidden risk.The most material tension is in the numbers management emphasizes less. Operating income rose only from $2.56 billion in 2024 to $2.7 billion in 2025, while revenue grew about 10%, so operating income as a share of revenue fell from about 2.2% to about 2.1%. Value creation charges were $98 million in the first quarter of 2026, versus $24 million a year earlier, and management says it expects additional charges over the program. The Insurance segment also depends heavily on government business: 83% of 2025 premiums and services revenue came from federal government contracts, including 14% from Florida Medicare Advantage contracts with CMS. The MaxHealth goodwill of approximately $800 million is still preliminary.